Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.52 USD | +1.19% | +20.72% | +78.43% |
23/04 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
22/04 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
Business Summary
Number of employees: 88
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alan Russell
FOU | Founder | 54 | 01/17/01 |
Kevin Koch
CEO | Chief Executive Officer | 63 | 01/17/01 |
R. Carruthers
DFI | Director of Finance/CFO | 66 | 16/20/16 |
Chief Tech/Sci/R&D Officer | 67 | 27/21/27 | |
Corporate Officer/Principal | 44 | 01/20/01 | |
Marc Semigran
PRN | Corporate Officer/Principal | 67 | 20/22/20 |
John Moore
LAW | General Counsel | 59 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Root
BRD | Director/Board Member | 64 | 01/19/01 |
Kevin Koch
CEO | Chief Executive Officer | 63 | 01/17/01 |
Peter Thompson
FOU | Founder | 64 | 01/17/01 |
Laura Brege
BRD | Director/Board Member | 66 | 01/20/01 |
Jonathan Fox
BRD | Director/Board Member | 67 | 02/23/02 |
Badreddin Edris
FOU | Founder | 37 | 01/17/01 |
Alan Russell
FOU | Founder | 54 | 01/17/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,410,476 | 92,999,680 ( 99.56 %) | 0 | 99.56 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+78.43% | 1.82B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- EWTX Stock
- Company Edgewise Therapeutics, Inc.